Chiese Journal of Surgery 

About: Chiese Journal of Surgery is an academic journal. The journal publishes majorly in the area(s): Hepatectomy & Survival rate. Over the lifetime, 32 publications have been published receiving 65 citations.

Double-blind randomized clinical trial in evaluating the efficacy and safety of rectum mucosa protector in the treatment of acute hemorrhoids

Abstract: Objective To evaluate the clinical efficacy and safety of Titanoreine suppository containing rectum mucosa protector in the treatment of acute hemorrhoids. [WT5”HZ]Methods[WT5”BZ] Double blind, placebo controlled randomized study was made in patients with acute hemorrhoids (within 4 days). The duration of study was seven days, during which Titanoreine suppositories and suppositories without mucosa protector were used twice daily in the study group and control group respectively. [WT5”HZ]Results[WT5”BZ] 123 patients completed the 7 day treatment (60 patients in the study group and 63 in the control group). Patients in the two groups were comparable in age, sex, diagnosis, history of hemorrhoids, symptoms and signs before the enrollment. No major adverse event was observed in both groups. Score reduction on pain, bleeding, and itchiness was significantly different between the two groups after 2 day treatment ( P 0 05). After 7 day treatment, score reduction on pain, bleeding, edema, erosion, and itchiness was significantly higher in the study group than in the control group ( P 0 05). [WT5”HZ]Conclusions[WT5”BZ] Data from the study showed that Titanoreine suppository containing rectum protector is safe and effective in the treatment of acute hemorrhoids.

Delayed xenograft rejection: pathology and IgG role

Abstract: Objective To study the characteristics patholog ical and the role of IgG in delayed xenograft rejection (DXR) in mouse to rat heart transplantation model Methods[WT5”B Z] The animals were divided in to 4 groups: group A ( n =6), controls recei ved no immunosuppression; group B ( n =6), treated with cyclospo rine (CsA)20 mg/kg every other day from day 0; group C ( n =6), added cycloph osphamide (CyP) 40 mg/kg at the day before operation, and then 20 mg/kg, every o ther day from the day after operation; group D ( n =5),combined CsA with CyP Serum IgG was detected by enzyme linked immunosorbent assay (ELISA) C 3, IgG and CD68 were determined by immunohistochemistry Results The pathology of rejected xenografts showed wide spread intravasc ular thrombosis, associated with a large number of infiltrated macrophages and coagulative necrosis Adminstration of CsA or CyP alone had no significant ef fect on xenograft survival However, combination of CsA with CyP significantly p rolonged the xenograft survival to (4 8±1 48)?d ( P 0 05 vs group A), and significantly decreased the serum IgG levels ( P 0 05), but it had no effect to decrease IgG deposition ( P 0 05) Conclusions Macrophages and increased IgG play an important role during DX R in the mouse to rat heart transplantation model Combination of CsA with CyP decreases the serum IgG levels in the xenografts and effectively prolongs the x enograft survival

Expression of angiopoietin-2 gene and its receptor Tie2 in hepatocellular carcinoma

Abstract: Objective To explore the roles of angiopoietin 2 and its receptor Tie2 in angiogenesis of hepatocellular carcinoma (HCC). [WT5”HZ]Methods[WT5”BZ] Expression of angiopoietin 2, Tie2 receptor and CD34 was determined with in situ hybridization and immunohistochemistry in 22 resected HCC, 8 cirrhotic and 8 control liver specimens. The correlation of levels of angiopoietin 2 and Tie2 receptor in HCC to the tumor's biological parameters was analyzed. [WT5”HZ]Results[WT5”BZ] CD34 was not expressed in control liver, scarcely expressed in cirrhotic liver (17 8±13 5/HP) but significantly expressed in HCC (86 3±34 8/HP, P 0 01). Tie2 receptor was not expressed in control liver, weakly expressed in cirrhotic liver (11 3±8 7/HP) but strongly expressed in the microvascular endothelium of HCC (52 4±16 7/HP, P 0 01). The level of Tie2 receptor expression in HCC was closely correlated with tumor diameter, angiogenesis and portal invasion, etc. Angiopoietin 2 was not expressed in control liver, weakly expressed in cirrhotic liver (11 2±9 7/HP) but strong expressed in HCC (36 4±17 5/HP). The level of its expression was closely related to angiogenesis, portal invasion and histological grading of HCC. [WT5”HZ]Conclusions[WT5”BZ] Angiogenesis is enhanced in HCC. Angiopoietin 2/Tie2 receptor expression in human HCC is closely related to angiogenesis, which might be involved in regulating angiogenesis of HCC.

Surgical treatment of primary liver cancer: report of 5?524 patients

Abstract: To study the results of surgical treatment of patients with primary liver cancer [WT5HZ]Methods[WT5BZ] From January 1960 to December 1998, 5 524 patients with pathologically proven primary liver cancer (PLC) underwent hepatectomy in our hospital The surgical results were compared in three periods: 1960-1977 (181 patients), 1978-1989 (921), and 1990-1998 (4?422) [WT5HZ]Results[WT5”FZ] Surgical outcomes were improved gradually as shown by the five year survival rate of 16 0% for the period of 1960-1977, 30 6% for 1978-1989 and 48 6% for 1990-1998 The operation mortality rate was in a decreased order from 8 48%, 0 43% to 0 31% during the consecutive periodsThese data indicated the progress in clinical research of primary liver cancer and the importance of surgery Normothermic intermittent interruption of the portal hepatis, transection with finger fracture and forceps, radical local resection and management of huge tumor involving the portal hepatis and inferior vena cava (IVC) were the main approaches in our practice [WT5HZ]Conclusions[WT5”FZ] Postoperative recurrence remains to be a problem Tumor free survival, however, could be increased by early detection and resection, preoperative transcatheter arterial chemoembolization (TACE), no iatrogenic dissemination, postoperative comprehensive treatment and reoperation The two stage operation is only indicated for unresectable primary liver cancer but not for all large tumors involving the portal hepatis or IVC The resectability should be judged carefully

Surgical treatment of carcinoma of the esophagus and gastric cardia: 34-year investigation

Abstract: Objective[WT5”BZ] To understand the progress in surgical treatment of 12?970 patients with carcinoma of the esophagus and gastric cardiac during 1965 1998. [WT5”HZ]Methods[WT5”BZ] The patients were divided into A,B and C groups: 3?155 patients (group A) were treated surgically in the first 14 years, 5?952 patients (group B) in the next 10 years, and 3?863 patients (group C) in the last 10 years. The early stage lesions (Tis,T1) were assigned as a separate group. The results of these groups were compared. [WT5”HZ]Results[WT5”BZ] The resectability for esophageal and gastric cardiac carcinoma was 94 0% and 84 4% respectively, and the overall resectability was 91 3%. The resectability for group A,B,C and the early stage group was 82 1%,85 1%,90 2% and 100%, respectively. The overall operative mortality was 1 8%; it was 4 4% for group A, 1 6% for group B, and 0 5% for group C. The overall 5 year survival was 31 6%.The 5 year survival for group A,B,C and the early stage group was 27 0%, 29 1%, 32 0% and 92 6%, respectively. Among the 3 temporal groups, differences were observed in terms of lesion stage, location and size, surgery with or without combined therapy and postoperative complications. [WT5”HZ]Conclusions[WT5”BZ] Best results were achieved in the early cases, with a resectability of 100% and a 5 year survival of 92 6%. The indications for surgical treatment were extended with increased resectability and decreased mortality. Subtotal esophagectomy combined with cervical esophagogastrostomy was advocated as the procedure of first choice for esophageal carcinoma in attempt to diminish the chance of recurrence, and to achieve better outcomes by using combined therapy for patients with ≥stage Ⅲ lesion.